Archives for 

Biologics Litigation

Bristol Myers Squibb, Bavarian Nordic, and Enzo Biochem file amicus brief supporting Amgen’s petition for en banc consideration of written description and enablement issues in Praluent® litigation

Biologics Litigation  •  U.S. Federal Circuit Decisions
As we reported previously, Amgen is seeking en banc review of the Federal Circuit panel decision vacating a permanent injunction that would have otherwise prohibited the sale of Sanofi and Regeneron’s Praluent® (alirocumab) product and remanding the […]

View More

Federal Circuit Oral Arguments in NYC today: A Review

Amgen v. Apotex (pegfilgrastim)  •  Biologics Litigation  •  BPCIA and Related U.S. Statutes  •  Janssen v. Celltrion (infliximab)  •  Patent Dance  •  U.S. Biosimilar Litigation News
As we noted earlier today, this week the Federal Circuit is holding oral argument at various venues in New York City. Two of today’s oral arguments were in biosimilar cases that we have been closely […]

View More

Amgen and AbbVie Settle Adalimumab BPCIA Litigation

AbbVie v. Amgen (adalimumab)  •  AbbVie v. Boehringer Ingelheim (adalimumab)  •  Approved Biosimilar Products  •  Biologics Litigation  •  Biosimilar News  •  U.S. Biosimilar Litigation News
Amgen has announced that it has settled all pending patent litigation regarding AMJEVITA, its biosimilar version of AbbVie’s Humira® (adalimumab). Amgen reports that AbbVie will grant patent licenses for the use and sale […]

View More